Trial Profile
MULTICENTER SECOND LINE STUDY OF AXITINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PROGRESSED WITH SORAFENIB STUDIO CLINICO MULTICENTRICO DI SECONDA LINEA DI AXITINIB IN PAZIENTI CON CARCINOMA EPATOCELLULARE (HCC) IN PROGRESSIONE DOPO TERAPIA CON SORAFENIB
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2014
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 09 Mar 2014 New trial record